Bone Marrow Microenvironment Niche Regulates miR-221/222 in Acute Lymphoblastic Leukemia.

Bone Marrow Microenvironment Niche Regulates miR-221/222 in Acute Lymphoblastic Leukemia.
复制标题

DOI:
10.1158/1541-7786.mcr-15-0474
复制
发表时间:
2016-10
期刊:
Molecular cancer research : MCR
影响因子:
--
通讯作者:
Gibson LF
Gibson LF
中科院分区:
其他
文献类型:
--
作者:
Moses BS;Evans R;Slone WL;Piktel D;Martinez I;Craig MD;Gibson LF

文献摘要

被引文献

相似文献

Acute lymphoblastic leukemia (ALL) has many features in common with normal B-cell progenitors, including their ability to respond to diverse signals from the bone marrow microenvironment (BMM) resulting in regulation of cell cycle progression and survival. Bone marrow derived cues influence many elements of both steady state hematopoiesis and hematopoietic tumor cell phenotypes through modulation of gene expression. MicroRNAs (miRNAs) are one regulatory class of small non-coding RNAs that have been shown to be increasingly important in diverse settings of malignancy. In the current study, miRNA profiles were globally altered in ALL cells following exposure to primary human bone marrow niche cells including bone marrow stromal cells (BMSC) and primary human osteoblasts (HOB). Specifically, mature miR-221 and miR-222 transcripts were decreased in ALL cells co-cultured with BMSC or HOB, coincident with increased p27 (CDKN1B), a previously validated target. Increased p27 protein in ALL cells exposed to BMSC or HOB is consistent with accumulation of tumor cells in the G0-phase of the cell cycle and resistance to chemotherapy induced death. Overexpression of miR-221 in ALL cells during BMSC or HOB co-culture prompted cell cycle progression and sensitization of ALL cells to cytotoxic agents, blunting the protective influence of the BMM. These novel observations indicate that BMM regulation of miR-221/222 contributes to marrow niche supported tumor cell quiescence and survival of residual cells. Niche influenced miR-221/222 may define a novel therapeutic target in ALL to be combined with existing cytotoxic agents to more effectively eradicate refractory disease that contributes to relapse.